13 completed, 5 recruiting, 3 terminated, 2 withdrawn. 26 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 13, Recruiting 5, Terminated 3, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow siltuximab: new trials by email Literature Review of siltuximab trials Research Report on siltuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-10-30 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma Siltuximab - CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 | |
| A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant Siltuximab, Melphalan - Multiple Myeloma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 215 | 2024-11-06 | 2026-10-01 |
| Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | Yuanquan Yang | 40 | 2024-07-09 | 2026-09-28 |
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH) Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo - Schwannomatosis, Schwannomas | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2023-08-31 | 2026-07-24 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Siltuximab - Cytokine Release Syndrome, ICANS | Phase 2 | Completed | University of Alabama at Birmingham | 20 | 2021-11-15 | 2026-07-27 |
| Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease Siltuximab - Idiopathic Multicentric Castleman's Disease | Phase 2 | Terminated | RECORDATI GROUP | 22 | 2021-03-31 | 2021-04-19 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia Siltuximab, Dexamethasone - COVID-19 | Phase 2 | Completed | Judit Pich MartÃnez | 163 | 2020-04-15 | 2023-09-21 |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Siltuximab, Spartalizumab - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | Emory University | 35 | 2020-01-17 | 2025-08-22 |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis Siltuximab, The M.D. Anderson Symptom Inventory (MDASI) - Multiple Myeloma, AL Amyloidosis | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-12-14 | 2025-11-04 |
| Siltuximab in Schizophrenia Siltuximab, normal saline - Schizophrenia, Psychotic Disorders | Phase 1 / Phase 2 | Unknown | Brian Miller | 30 | 2016-05-01 | 2023-07-21 |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Lenalidomide, Bortezomib, Siltuximab - Myeloma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 14 | 2012-05-01 | 2015-06-19 |
| A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma Siltuximab, Placebo - High-risk Smoldering Multiple Myeloma | Phase 2 | Completed | Janssen Research & Development, LLC | 85 | 2012-03-01 | 2020-01-27 |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome Siltuximab, Placebo, Best supportive care (BSC) - Myelodysplastic Syndrome | Phase 2 | Terminated | Janssen Research & Development, LLC | 76 | 2011-11-01 | 2014-09-29 |
| A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Siltuximab - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 60 | 2011-04-01 | 2018-05-22 |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Siltuximab, Placebo, Best Supportive Care (BSC) - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 79 | 2010-03-18 | 2018-03-21 |
| A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib) - Multiple Myeloma | Phase 2 | Completed | Janssen Research & Development, LLC | 118 | 2009-06-01 | 2014-11-18 |
| A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors CNTO 328; Anti-interleukin-6 monoclonal antibody - Ovarian Neoplasms, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | Centocor, Inc. | 84 | 2009-03-01 | 2014-05-14 |
Showing 20 of 26. Sign in to see all of them.
Multiple Myeloma (9) · Cytokine Release Syndrome (3) · Multi-centric Castleman's Disease (3) · Neoplasms, Plasma Cell (3) · Carcinoma, Renal Cell (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Burkitt Lymphoma (1) · COVID-19 (1) · Chronic Pain (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1) · Immunoglobulin Light-chain Amyloidosis (1)
Janssen Research & Development, LLC (6) · Centocor, Inc. (4) · Memorial Sloan Kettering Cancer Center (2) · Merck Sharp & Dohme LLC (2) · SWOG Cancer Research Network (2) · Brian Miller (1) · Emory University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jack Khouri, MD (1) · Judit Pich MartÃnez (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · RECORDATI GROUP (1) · University of Alabama at Birmingham (1) · Yuanquan Yang (1)
United States (20) · Spain (10) · France (9) · Belgium (7) · United Kingdom (7) · Israel (6) · Netherlands (6) · Germany (5) · Australia (4) · Canada (4) · Russia (4) · South Korea (4) · Brazil (3) · China (3) · Greece (3)
Amitkumar Mehta, MD (1) · Chris Keuker, MD (1) · Gunjan Shah (1) · Gunjan Shah, MD, MS (1) · Jacek K. Pinski, MD (1) · Jacek Pinski, MD (1) · Jack Khouri, MD (1) · Jatin J. Shah, MD (1) · Olatunji Alese, MD (1) · Philip C. Mack, Ph.D. (1)
PMID 20484019, PMID 24833354, PMID 25042199, PMID 25294016, PMID 28087540, PMID 30890552, PMID 35793409, PMID 36798353
2008 (2), 2025 (2), U10CA032102 (2), 2009 (1), P30CA138292 (1)